Metrogyl 400 mg (Metronidazole) Perth — Anaerobic & Protozoal Infections | Western Australia | 2026
Product Name
Metrogyl 400 mg Tablets
Product Details
Metrogyl 400 mg contains Metronidazole 400 mg, a nitroimidazole antibiotic and antiprotozoal medicine used to treat infections caused by anaerobic bacteria and susceptible protozoa. It is commonly prescribed for gastrointestinal, gynecological, dental, skin, bone, joint, and intra-abdominal infections. It is also used in combination therapy for specific gastrointestinal infections and for the prevention of postoperative anaerobic infections. In Australia, Metrogyl is a Schedule 4 (Prescription Only Medicine).
Product Specifications
| Brand Name | Metrogyl 400 mg |
| Generic Name | Metronidazole |
| Strength | 400 mg |
| Dosage Form | Oral Tablet |
| Drug Class | Nitroimidazole Antibiotic & Antiprotozoal |
| Packing | Strip/Bottle (varies by manufacturer and market) |
| Route of Administration | Oral |
| Prescription Status | Prescription Only Medicine (S4 in Australia) |
| Storage | Store below 30°C in a dry place, protected from light. |
Key Features
- Contains Metronidazole 400 mg for effective antimicrobial therapy.
- Active against a broad range of anaerobic bacterial infections.
- Effective treatment for protozoal infections, including amoebiasis and giardiasis.
- Commonly prescribed for bacterial vaginosis, pelvic infections, dental infections, and intra-abdominal infections.
- May be used before or after surgery to help prevent anaerobic bacterial infections.
- Well-established antibiotic with decades of clinical use worldwide.
- Available only with a valid medical prescription in Australia.
Industry Update
Demand for Metrogyl 400 mg (Metronidazole) remains stable across Perth and Western Australia due to its continued importance in treating anaerobic bacterial and protozoal infections. Hospitals, dental clinics, general practitioners, and infectious disease specialists continue to prescribe metronidazole for gastrointestinal, gynecological, and postoperative infections.
Australia experienced temporary supply disruptions affecting some metronidazole brands during 2025–2026 due to manufacturing issues and increased demand. However, regulatory authorities reported that alternative brands remained available, and supply of Metrogyl 400 mg has since been restored.
In 2026, healthcare providers in Western Australia continue to emphasize:
- Appropriate antibiotic prescribing to reduce antimicrobial resistance.
- Completing the full prescribed treatment course.
- Avoiding alcohol while taking metronidazole and for at least 24–48 hours after the final dose, as advised by healthcare professionals.
- Continued availability of prescription metronidazole through Australian pharmacies under the Pharmaceutical Benefits Scheme (PBS), where applicable.
